^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Serotonin 1A-2A-2B-2C receptor antagonist

    Related drugs:
    15d
    CBT-BDNF-SCZ: Cognitive Behavioral Therapy Added to Risperidone for Schizophrenia (clinicaltrials.gov)
    P=N/A, N=42, Completed, Hasanuddin University
    New trial
    16d
    CINEMA: Cerebellum-based Imaging Neural Markers for Antipsychotic Response (clinicaltrials.gov)
    P4, N=120, Recruiting, Northwell Health | Phase classification: P --> P4
    Phase classification
    20d
    SEP-1: Subjective Experience Following Psilocybin (clinicaltrials.gov)
    P2, N=128, Recruiting, University of Calgary | Not yet recruiting --> Recruiting
    Enrollment open
    20d
    Adjunct Sphenopalatine Ganglion Analgesia for Rapid Discharge (ASGARD) among emergency department patients with headache (ACTRN12626000624381)
    P=N/A, N=104, Not yet recruiting, Eastern Health
    New trial • Head-to-Head
    |
    chlorpromazine
    1m
    Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects (clinicaltrials.gov)
    P1, N=85, Recruiting, Medical University of Vienna
    Trial initiation date
    1m
    WSE-SCZ: Effectiveness of Ashwagandha in Schizophrenia Patients on Risperidone (clinicaltrials.gov)
    P2, N=80, Completed, Hasanuddin University
    New P2 trial
    1m
    BEEST: Biomarkers to Enhance Early Schizophrenia Treatment (clinicaltrials.gov)
    P4, N=180, Recruiting, Northwell Health | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1)
    2ms
    ASH-BDNF: Effect of Ashwagandha as Adjunct Therapy on BDNF and Cognitive Function in Schizophrenia Patients (clinicaltrials.gov)
    P=N/A, N=80, Completed, Hasanuddin University
    New trial
    2ms
    Hepatoprotective effect of engeletin against risperidone-induced liver injury in rats involvement of TGF-β1/Smad and NF-κB pathways. (PubMed, Tissue Cell)
    In addition, advanced molecular docking analysis demonstrated strong binding affinity of engeletin with the key regulatory proteins SMAD3 (-9.3 kcal/mol) and NF-κB p65 (-9.1 kcal/mol), providing strong evidence that ENG can directly interact with the central regulators of the TGF-β1/Smad and NF-κB signaling pathways. In conclusion, ENG significantly ameliorated RIS-induced hepatotoxicity, highlighting its potential as hepatoprotective adjuvant therapy.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • SMAD4 (SMAD family member 4) • TNFA (Tumor Necrosis Factor-Alpha) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • CASP3 (Caspase 3) • TGFB1 (Transforming Growth Factor Beta 1) • CASP9 (Caspase 9) • COL1A1 (Collagen Type I Alpha 1 Chain) • IL1B (Interleukin 1, beta) • SMAD3 (SMAD Family Member 3) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    2ms
    CBT-SCZ-NLR: Effect of Cognitive Behavioral Therapy on Auditory Hallucinations and NLR in Schizophrenia Patients (clinicaltrials.gov)
    P=N/A, N=50, Completed, Hasanuddin University
    New trial
    2ms
    Risperidone Treatment in Children and Adolescents: A Naturalistic Observational Study of Metabolic, Cardiac, and Clinical Outcomes. (PubMed, J Child Adolesc Psychopharmacol)
    Within 6 months of initiation, risperidone use in drug-naive pediatric patients was associated with increased weight and abdominal adiposity, early prolactin elevation, HDL reduction, and clinical improvement. Waist circumference showed a strong dose-dependent association and should be routinely monitored along with metabolic and endocrine parameters.
    Clinical data • Observational data • Journal
    |
    PRL (Prolactin)
    2ms
    PSY-PGx: Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders (clinicaltrials.gov)
    P=N/A, N=1470, Recruiting, Maastricht University Medical Center | Not yet recruiting --> Recruiting | N=820 --> 1470
    Enrollment open • Enrollment change